Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114326 | 0.94 | OPRM1 (0.57) | OPRM1OPRD1OPRK1ERAP2LNPEP | |
| SCHEMBL31114531 | 0.93 | OPRM1 (0.62) | OPRM1OPRD1NTSR2NTSR1 | |
| SCHEMBL31519062 | 0.92 | OPRM1 (0.64) | OPRM1OPRD1NTSR2NTSR1F2 | |
| SCHEMBL31114393 | 0.91 | OPRM1 (0.62) | OPRM1OPRD1NTSR2NTSR1F2 | |
| SCHEMBL30839278 | 0.89 | OPRM1 (0.57) | OPRM1OPRD1OPRK1NTSR2NTSR1 | |
| SCHEMBL31114331 | 0.89 | OPRM1 (0.62) | OPRM1OPRD1NTSR2NTSR1 | |
| SCHEMBL31114433 | 0.89 | OPRM1 (0.65) | OPRM1OPRD1NTSR2NTSR1 | |
| SCHEMBL31114345 | 0.89 | OPRM1 (0.58) | OPRM1OPRD1NTSR2NTSR1F2 | |
| SCHEMBL31114060 | 0.88 | OPRM1 (0.61) | OPRM1OPRD1NTSR2NTSR1F2 | |
| SCHEMBL31114372 | 0.88 | OPRM1 (0.59) | OPRM1OPRD1NTSR2NTSR1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218016-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20230331792-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331792-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | VIP, MLX, IAPP | OPRM1 416/4885OPRD1 389/4885OPRK1 721/4885 |
| US-20240218016-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | VIP, ARGLU1, NGLY1 | OPRM1 722/4885OPRD1 829/4885OPRK1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.